Skip to main content
SpringerLink
Log in
Book cover

Histamine in Inflammation pp 125–140Cite as

The Future Antihistamines: Histamine H3 and H4 Receptor Ligands

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 709))

Abstract

The field of histamine research has progressed far from a century ago when the first biological functions of histamine were identified. It is now known that histamine function is mediated by four histamine receptors, which belong to the G-protein-coupled receptor family. While antihistamines that target the first two receptors have enjoyed clinical and commercial success, efforts to find new antihistamines against the histamine H3 and H4 receptors are still in the early stages. Here we will review the therapeutic potential of targeting these new histamine receptors.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yamashita M, Fukui H, Sugama K et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci USA 1991; 88(24): 11515–11519.

    PubMed  CAS  Google Scholar 

  2. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7(1):41–53.

    PubMed  CAS  Google Scholar 

  3. McQuade RD, Richlan K, Duffy RA et al. In vivo binding properties of nonsedating antihistamines to CNS histamine receptors. Drug Dev Res 1990; 20(3):301–306.

    CAS  Google Scholar 

  4. Gantz I, Munzert G, Tashiro T et al. Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun 1991; 178(3):1386–1392.

    PubMed  CAS  Google Scholar 

  5. Hill SJ, Ganellin CR, Timmerman H et al. International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49(3):253–278.

    PubMed  CAS  Google Scholar 

  6. Mossner J, Caca K. Developments in the inhibition of gastric acid secretion. Eur J Clin Invest 2005; 35(8):469–475.

    PubMed  CAS  Google Scholar 

  7. Arrang JM, Garbarg M, Schwartz JC. Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302(5911):832–837.

    PubMed  CAS  Google Scholar 

  8. Lovenberg TW, Roland BL, Wilson SJ et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999; 55(6):1101–1107.

    PubMed  CAS  Google Scholar 

  9. Oda T, Morikawa N, Saito Y et al. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275(47):36781–36786.

    PubMed  CAS  Google Scholar 

  10. Liu C, Ma X-J, Jiang X et al. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 2001; 59(3):420–426.

    PubMed  CAS  Google Scholar 

  11. Stocking EM, Letavic MA. Histamine H3 antagonists as wake-promoting and pro-cognitive agents. Curr Top Med Chem 2008; 8(11):988–1002.

    PubMed  CAS  Google Scholar 

  12. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008; 31(12):2163–2181.

    PubMed  CAS  Google Scholar 

  13. Bonaventure P, Letavic M, Dugovic C et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007; 73(8):1084–1096.

    PubMed  CAS  Google Scholar 

  14. Tiligada E, Zampeli E, Sander K et al. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009; 18(10): 1519–1531.

    PubMed  CAS  Google Scholar 

  15. Zhang M, Ballard ME, Pan L et al. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res 2005; 1045(1–2):142–149.

    PubMed  CAS  Google Scholar 

  16. Ligneau X, Perrin D, Landais L et al. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007; 320(1):365–375.

    PubMed  CAS  Google Scholar 

  17. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369(9560):499–511.

    PubMed  Google Scholar 

  18. Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005; 28(6):754–763.

    PubMed  Google Scholar 

  19. Nishino S, Fujiki N, Ripley B et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001; 313(3):125–128.

    PubMed  CAS  Google Scholar 

  20. Lin JS, Dauvilliers Y, Arnulf I et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008; 30(1):74–83.

    PubMed  Google Scholar 

  21. Arnulf I. Results of clinical trials of tiprolisant in narcolepsy and Parkinson’s disease. S.19.05 Paper presented at: 22nd ECNP Congress, 2009; Istanbul, Turkey.

    Google Scholar 

  22. Schwartz JC. Preclinical and clinical pharmacology of H3 receptor inverse agonist. S. 19.02 Paper presented at: 22nd ECNP Congress, 2009; Istanbul, Turkey.

    Google Scholar 

  23. Esbenshade TA, Browman KE, Bitner RS et al. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154(6):1166–1181.

    PubMed  CAS  Google Scholar 

  24. Medhurst AD, Atkins AR, Beresford IJ et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007; 321(3): 1032–1045.

    PubMed  CAS  Google Scholar 

  25. Medhurst AD, Briggs MA, Bruton G et al. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem Pharmacol 2007; 73(8):1182–1194.

    PubMed  CAS  Google Scholar 

  26. Alzheimer’s Association. 2009 Alzheimer’s disease facts and figures. Alzheimers Dement 2009; 5(3):234–270.

    Google Scholar 

  27. Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004; 103(1):1–20.

    PubMed  CAS  Google Scholar 

  28. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004; 13(10):1237–1248.

    PubMed  CAS  Google Scholar 

  29. Medhurst AD, Roberts JC, Lee J et al. Characterization of histamine H3 receptors in Alzheimer’s Disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 2009; 157(1):130–138.

    PubMed  CAS  Google Scholar 

  30. Bhugra D. The global prevalence of schizophrenia. PLoS Med 2005; 2(5):e151.

    PubMed  Google Scholar 

  31. Ligneau X, Perrin D, Landais L et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther 2007; 320(1):365–375.

    PubMed  CAS  Google Scholar 

  32. Fox GB, Esbenshade TA, Pan JB et al. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia. Inflamm Res 2005; 54(Suppl 1):S23–S24.

    PubMed  CAS  Google Scholar 

  33. NCT00690274. Study to demonstrate cognitive enhancing effects of BF2.649. www.clinicaltrials.gov.

  34. Polanczyk G, de Lima MS, Horta BL et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 2007; 164(6):942–948.

    PubMed  Google Scholar 

  35. Biederman J, Faraone SV, Taylor A et al. Diagnostic continuity between child and adolescent ADHD: findings from a longitudinal clinical sample. J Am Acad Child Adolesc Psychiatry 1998; 37(3):305–313.

    PubMed  CAS  Google Scholar 

  36. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46(9):1234–1242.

    PubMed  CAS  Google Scholar 

  37. Kobau R, Zahran H, Thurman David J et al. Epilepsy surveillance among adults—19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ 2008; 57(6):1–20.

    PubMed  Google Scholar 

  38. Harada C, Fujii Y, Hirai T et al. Inhibitory effect of iodophenpropit, a selective histamine H3 antagonist, on amygdaloid kindled seizures. Brain Res Bull 2004; 63(2): 143–146.

    PubMed  CAS  Google Scholar 

  39. Harada C, Hirai T, Fujii Y et al. Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia. Methods Find Exp Clin Pharmacol 2004; 26(4):263–270.

    PubMed  CAS  Google Scholar 

  40. Jiang X, Chen A, Li H. Histaminergic modulation of excitatory synaptic transmission in the rat basolateral amygdala. Neuroscience 2005; 131(3):691–703.

    PubMed  CAS  Google Scholar 

  41. Schwartz J-C, Lecomte J-M, Schwartz J-C et al. (Bioprojet, Fr.). assignee. Treatment of epilepsy with non-imidazole alkylamine histamine H3 receptor ligands. US Patent 2006103537. 20060330, 2006.

    Google Scholar 

  42. Yoshimoto R, Miyamoto Y, Shimamura K et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci USA 2006; 103(37):13866–13871.

    PubMed  CAS  Google Scholar 

  43. Masaki T, Yoshimatsu H, Chiba S et al. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001; 50(2):376–384.

    PubMed  CAS  Google Scholar 

  44. Tokita S, Takahashi K, Kotani H. Recent advances in Mol Pharmacol of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 2006; 101(1):12–18.

    PubMed  CAS  Google Scholar 

  45. Ishizuka T, Hatano K, Murotani T et al. Comparison of the effect of an H(3)-inverse agonist on energy intake and hypothalamic histamine release in normal mice and leptin resistant mice with high fat diet-induced obesity. Behav Brain Res 2008; 188(2):250–254.

    PubMed  CAS  Google Scholar 

  46. Raga MM, Sallares J, Guerrero M et al. (Ferrer Internacional, S.A., Spain). assignee. Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine monohydrochloride as a histamine H3 receptor ligand. US Patent 2006084833. 20060206, 2006.

    Google Scholar 

  47. Stander S, Schmelz M. Chronic itch and pain—similarities and differences. Eur J Pain 2006; 10(5):473–478.

    PubMed  Google Scholar 

  48. Baron R, Schwarz K, Kleinert A et al. Histamine-induced itch converts into pain in neuropathic hyperalgesia. Neuroreport 2001; 12(16):3475–3478.

    PubMed  CAS  Google Scholar 

  49. Mobarakeh JI, Takahashi K, Yanai K. Enhanced morphine-induced antinociception in histamine H3 receptor gene knockout mice. Neuropharmacology 2009; 57(4):409–414.

    PubMed  CAS  Google Scholar 

  50. Smith FM, Haskelberg H, Tracey DJ et al. Role of histamine H3 and H4 receptors in mechanical hyperalgesia following peripheral nerve injury. Neuroimmunomodulation 2007; 14(6):317–325.

    PubMed  CAS  Google Scholar 

  51. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection and diagnosis. J Allergy Clin Immunol 2001; 108(1 Suppl):S2–S8.

    PubMed  CAS  Google Scholar 

  52. Taylor-Clark T, Sodha R, Warner B et al. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005; 144(6):867–874.

    PubMed  CAS  Google Scholar 

  53. McLeod RL, Mingo GG, Herczku C et al. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999; 13(5):391–399.

    PubMed  CAS  Google Scholar 

  54. Romero FA, Allan RJ, Phillips PG et al. The Effects of an H3 Receptor Antagonist in a Nasal Allergen Challenge Model. J Allergy Clin Immunol 2010; 125(2):AB191.

    Google Scholar 

  55. Masini E, Fabbroni V, Giannini L et al. Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res 2005; 54(Suppl 1):S80–S81.

    PubMed  CAS  Google Scholar 

  56. Medina V, Croci M, Crescenti E et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 2008; 7(1):28–35.

    PubMed  CAS  Google Scholar 

  57. Cricco GP, Mohamad NA, Sambuco LA et al. Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors. Inflamm Res 2008; 57(Suppl 1):S23–S24.

    PubMed  CAS  Google Scholar 

  58. Huang J-F, Thurmond R. The new biology of histamine receptors. Curr Allergy Asthma Rep 2008; 8(1):21–27.

    PubMed  CAS  Google Scholar 

  59. Strakhova MI, Nikkel AL, Manelli AM et al. Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Research 2009; 1250(Complete):41–48.

    PubMed  CAS  Google Scholar 

  60. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31(1): 143–178.

    PubMed  CAS  Google Scholar 

  61. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3(10):831–844.

    PubMed  CAS  Google Scholar 

  62. Busse WW, Swenson CA. The relationship between plasma histamine concentrations and bronchial obstruction to antigen challenge in allergic rhinitis. J Allergy Clin Immunol 1989; 84(5 Pt 1):658–666.

    PubMed  CAS  Google Scholar 

  63. Van Ganse E, Kaufman L, Derde MP et al. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10(10):2216–2224.

    PubMed  Google Scholar 

  64. Leopold JD, Hartley JP, Smith AP. Effects of oral H1 and H2 receptor antagonists in asthma. British J Clin Pharmacol 1979; 8(3):249–251.

    CAS  Google Scholar 

  65. Nogrady SG, Hahn AG. H2-receptor blockade and exercise-induced asthma. Br J Clin Pharmacol 1984; 18(5):795–797.

    PubMed  CAS  Google Scholar 

  66. Hofstra CL, Desai PJ, Thurmond RL et al. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003; 305(3):1212–1221.

    PubMed  CAS  Google Scholar 

  67. Ling P, Ngo K, Nguyen S et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 2004; 142(1):161–171.

    PubMed  CAS  Google Scholar 

  68. Dunford PJ, O’Donnell N, Riley JP et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T-cells. J Immunol 2006; 176(11):7062–7070.

    PubMed  CAS  Google Scholar 

  69. Gutzmer R, Mommert S, Gschwandtner M et al. The histamine H4 receptor is functionally expressed on TH2 cells. J Allergy Clin Immunol 2009; 123(3):619–625.

    PubMed  CAS  Google Scholar 

  70. Deml K-F, Beermann S, Neumann D et al. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol 2009; 76(5):1019–1030.

    PubMed  CAS  Google Scholar 

  71. Pichavant M, Matangkasombut P, DeKruyff RH et al. Natural killer T-cells regulate the development of asthma. Expert Rev Clin Immunol 2009; 5(3):251–260.

    PubMed  CAS  Google Scholar 

  72. Leite-de-Moraes MC, Diem S, Michel M-L et al. Cutting Edge: Histamine Receptor H4 Activation Positively Regulates In Vivo IL-4 and IFN-gamma Production by Invariant NKT Cells. J Immunol 2009; 182(3):1233–1236.

    PubMed  CAS  Google Scholar 

  73. Kohyama T, Yamauchi Y, Takizawa H et al. Histamine stimulates human lung fibroblast migration. Mol Cell Biochem 2010; 337(1–2):77–81.

    PubMed  CAS  Google Scholar 

  74. Morgan RK, McAllister B, Cross L et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T-cells and inhibits allergic asthma in a murine model. J Immunol 2007; 178(12):8081–8089.

    PubMed  CAS  Google Scholar 

  75. Steinhoff M, Neisius U, Ikoma A et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. Journal of Neuroscience 2003; 23(15):6176–6180.

    PubMed  CAS  Google Scholar 

  76. Johnson HH Jr, DeOreo GA, Lascheid WP et al. Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 1960; 34:237–238.

    PubMed  CAS  Google Scholar 

  77. Juhlin L. Localization and content of histamine in normal and diseased skin. Acta Dermato-Venereologica 1967; 47(6):383–391.

    PubMed  CAS  Google Scholar 

  78. Greaves MW, Soendergaard J. Urticaria pigmentosa and factitious urticaria. Arch Dermatol 1970; 101(4):418–425.

    PubMed  CAS  Google Scholar 

  79. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol 1978; 61(6):350–354.

    PubMed  CAS  Google Scholar 

  80. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. The Journal of Allergy and Clinical Immunology. 2006;118(1):152–169.

    PubMed  Google Scholar 

  81. Homey B, Steinhoff M, Ruzicka T et al. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006; 118(1): 178–189.

    PubMed  CAS  Google Scholar 

  82. Bieber T. Atopic Dermatitis. New England Journal of Medicine 2008; 358(14):1483–1494.

    PubMed  CAS  Google Scholar 

  83. Raap U, Wichmann K, Bruder M et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008; 122(2):421–423.

    PubMed  CAS  Google Scholar 

  84. Sonkoly E, Muller A, Lauerma AI et al. IL-31: a new link between T-cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117(2):411–417.

    PubMed  CAS  Google Scholar 

  85. Gambichler T, Kreuter A, Tomi NS et al. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol 2008; 158(5): 1117–1120.

    PubMed  CAS  Google Scholar 

  86. Neis MM, Peters B, Dreuw A et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006; 118(4):930–937.

    PubMed  CAS  Google Scholar 

  87. Ikawa Y, Shiba K, Ohki E et al. Comparative study of histamine H4 receptor expression in human dermal fibroblasts. J Toxicol Sci 2008; 33(4):503–508.

    PubMed  CAS  Google Scholar 

  88. Dijkstra D, Stark H, Chazot PL et al. Human Inflammatory Dendritic Epidermal Cells Express a Functional Histamine H4 Receptor. J Invest Dermatol 2008; 128(7): 1696–1703.

    PubMed  CAS  Google Scholar 

  89. Baumer W, Wendorff S, Gutzmer R et al. Histamine H4 receptors modulate dendritic cell migration through skin—immunomodulatory role of histamine. Allergy 2008; 63(10):1387–1394.

    PubMed  CAS  Google Scholar 

  90. Cowden JM, Zhang M, Dunford PJ et al. The Histamine H4 Receptor Mediates Inflammation and Pruritus in Th2-Dependent Dermal Inflammation. J Invest Dermatol 2010; 130(4):1023–1033.

    PubMed  CAS  Google Scholar 

  91. Park CW, Lee BH, Han HJ et al. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol 2005; 152(6): 1173–1181.

    PubMed  CAS  Google Scholar 

  92. Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1a (MIP-1a), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clinical and Experimental Immunology 1999; 117(2):237–243.

    PubMed  CAS  Google Scholar 

  93. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94(2):870–876.

    PubMed  CAS  Google Scholar 

  94. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. The J Allergy Clin Immunol 2006; 118(1): 152–169.

    Google Scholar 

  95. Avgerinou G, Goules AV, Stavropoulos PG et al. Atopic dermatitis: new immunologic aspects. Int J Dermatol 2008; 47(3):219–224.

    PubMed  CAS  Google Scholar 

  96. Seike M, Furuya K. Thioperamide (H3 and H4 receptor antagonist) improves ecezematous lesions in murine contact dermatitis. Sagami Joshi Daigaku Kiyo Shizenkei 2007; 71B:7–13.

    CAS  Google Scholar 

  97. Kaplan AP. Chronic urticaria: Pathogenesis and treatment. J Allergy Clin Immunol 2004; 114(3):465–474.

    PubMed  CAS  Google Scholar 

  98. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135(12): 1522–1525.

    PubMed  CAS  Google Scholar 

  99. Yu F, Wolin RL, Wei J et al. Pharmacological characterization of oxime agonists of the histamine H4 receptor. J Receptor Ligand Channel Res 2010; 3:37–49.

    CAS  Google Scholar 

  100. Dunford PJ, Williams KN, Desai PJ et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119(1):176–183.

    PubMed  CAS  Google Scholar 

  101. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br J Pharmacol 2004; 142:374–380.

    PubMed  CAS  Google Scholar 

  102. Yamaura K, Oda M, Suwa E et al. Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J Toxicol Sci 2009; 34(4):427–431.

    PubMed  CAS  Google Scholar 

  103. Rossbach K, Wendorff S, Sander K et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Experimental Dermatology 2009; 18(1):57–63.

    PubMed  CAS  Google Scholar 

  104. Connelly WM, Shenton FC, Lethbridge N et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 2009; 157(1):55–63.

    PubMed  CAS  Google Scholar 

  105. Breunig E, Michel K, Zeller F et al. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol (Oxford, United Kingdom) 2007; 583(2):731–742.

    CAS  Google Scholar 

  106. Jokuti A, Hellinger E, Hellinger A et al. Histamine H4 receptor expression is elevated in human nasal polyp tissue. Cell Biol Int 2007; 31(11):1367–1370.

    PubMed  CAS  Google Scholar 

  107. Takahashi Y, Kagawa Y, Izawa K et al. Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. International Immunopharmacology 2009; 9(6):734–738.

    PubMed  CAS  Google Scholar 

  108. Lock R, Collingwood S, Ratcliffe A. Emerging therapies for respiratory diseases. Drug News Perspect 2007; 20(9):593–600.

    PubMed  Google Scholar 

  109. Tuomisto L, Kilpelainen H, Riekkinen P. Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis. Agents and Actions 1983; 13(2–3):255–257.

    PubMed  CAS  Google Scholar 

  110. Petersen LJ, Hansen U, Kristensen JK et al. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Dermato-Venereologica 1998; 78(3):190–193.

    PubMed  CAS  Google Scholar 

  111. Frewin DB, Cleland LG, Jonsson JR et al. Histamine levels in human synovial fluid. J Rheumatol 1986; 13(1):13–14.

    PubMed  CAS  Google Scholar 

  112. Zhang M, Venable JD, Thurmond RL. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 2006; 15(11):1443–1452.

    PubMed  CAS  Google Scholar 

  113. Winterkamp S, Weidenhiller M, Otte P et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97(12):3071–3077.

    PubMed  CAS  Google Scholar 

  114. Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997; 42(2):394–403.

    PubMed  CAS  Google Scholar 

  115. Raithel M, Matek M, Baenkler HW et al. Mucosal histamine content and histamine secretion in Crohn’s disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995; 108(2):127–133.

    PubMed  CAS  Google Scholar 

  116. Ibrahim MZM, Reder AT, Lawand R et al. The mast cells of the multiple sclerosis brain. Journal of Neuroimmunology 1996; 70(2):131–138.

    PubMed  CAS  Google Scholar 

  117. Toms R, Weiner HL, Johnson D. Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. Journal of Neuroimmunology 1990; 30(2–3):169–177.

    PubMed  CAS  Google Scholar 

  118. Crisp AJ. Mast cells in rheumatoid arthritis. J R Soc Med 1984; 77(6):450–451.

    PubMed  CAS  Google Scholar 

  119. Godfrey HP, Ilardi C, Engber W et al. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis and Rheumatism 1984; 27(8):852–856.

    PubMed  CAS  Google Scholar 

  120. Dvorak AM, McLeod RS, Onderdonk A et al. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. Int Arch Allergy Immunol 1992; 99(1):74–83.

    PubMed  CAS  Google Scholar 

  121. King T, Biddle W, Bhatia P et al. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992; 37(4):490–495.

    PubMed  CAS  Google Scholar 

  122. Secor VH, Secor WE, Gutekunst C-A et al. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000; 191(5):813–821.

    PubMed  CAS  Google Scholar 

  123. Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. Molecular Immunology 2002; 38(16–18):1373–1378.

    PubMed  CAS  Google Scholar 

  124. Rajasekaran N, Solomon S, Watanabe T et al. Histidine decarboxylase but not histamine receptor 1 or 2 deficiency protects from K/BxN serum-induced arthritis. Int Immunol 2009; 21(11):1263–1268.

    PubMed  CAS  Google Scholar 

  125. Varga C, Horvath K, Berko A et al. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 2005; 522(1–3):130–138.

    PubMed  CAS  Google Scholar 

  126. Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10years on. Eur J Pharmacol 2009; 623(Suppl.):S17–S25.

    Google Scholar 

  127. Altenbach RJ, Adair RM, Bettencourt BM et al. Structure-Activity Studies on a Series of a 2-Aminopyrimidine-Containing Histamine H4 Receptor Ligands. J Med Chem 2008; 51(20):6571–6580.

    PubMed  CAS  Google Scholar 

  128. Coruzzi G, Adami M, Guaita E et al. Anti-inflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol 2007; 563(1–3):240–244.

    PubMed  CAS  Google Scholar 

  129. Cowart MD, Altenbach RJ, Liu H et al. Rotationally Constrained 2,4-Diamino-5,6-disubstituted Pyrimidines: A New Class of Histamine H4 Receptor Antagonists with Improved Druglikeness and in Vivo Efficacy in Pain and Inflammation Models. J Med Chem 2008; 51(20):6547–6557.

    PubMed  CAS  Google Scholar 

  130. Hsieh GC, Chandran P, Salyers AK et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav 2010; 95(1):41–50.

    PubMed  CAS  Google Scholar 

  131. Liu H, Altenbach RJ, Carr TL et al. cis-4-(Piperazin-l-yl)-5,6,7a,8,9,10,1 1,1 1a-octahydro benzofuro[2,3-h]quinazolin-2-amine (A-987306), A New Histamine H4R Antagonist that Blocks Pain Responses against Carrageenan-induced Hyperalgesia. J Med Chem 2008; 51(22):7094–7098.

    PubMed  CAS  Google Scholar 

  132. Cianchi F, Cortesini C, Schiavone N et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005; 11(19, Pt. 1):6807–6815.

    PubMed  CAS  Google Scholar 

  133. Petit-Bertron A-F, Machavoine F, Defresne MP et al. H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells. PLoS One 2009; 4(8):e6504.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, California, 92121, USA

    Robin L. Thurmond

Authors
  1. Fuqu Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Bonaventure
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robin L. Thurmond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin L. Thurmond .

Editor information

Editors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, California, USA

    Robin L. Thurmond PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Landes Bioscience and Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Yu, F., Bonaventure, P., Thurmond, R.L. (2010). The Future Antihistamines: Histamine H3 and H4 Receptor Ligands. In: Thurmond, R.L. (eds) Histamine in Inflammation. Advances in Experimental Medicine and Biology, vol 709. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8056-4_12

Download citation

Publish with us

Policies and ethics

Search

Navigation